查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971787

抗體藥物複合體(ADC) 市場分析及預測至 2035 年：按類型、產品類型、服務、技術、應用、最終用戶、製程、階段、解決方案、模式

Antibody Drug Conjugate Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Stage, Solutions, Mode
出版日期: | 出版商: Global Insight Services | 英文 303 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

抗體藥物複合體（ADC）市場預計將從2024年的210億美元成長到2034年的439億美元，複合年成長率約為7.7%。抗體藥物複合體（ADC）市場涵蓋將單株抗體與細胞毒性藥物結合的療法，這些療法能夠針對特定的癌細胞，同時最大限度地減少對健康組織的損傷。該市場的成長動力主要來自於標靶癌症治療的進步、癌症發生率的上升以及藥物遞送系統的技術創新。正在進行的臨床試驗、監管核准以及主要行業參與者之間的策略聯盟也進一步推動了市場成長。

抗體藥物複合體(ADC) 市場持續穩定成長，這主要得益於標靶癌症治療和個人化醫療的進步。腫瘤學領域處於領先地位，其中乳癌和骨髓惡性腫瘤因其巨大的未滿足醫療需求而成為重點關注領域。在這些領域中，乳癌ADC 已展現出令人鼓舞的臨床療效，並取得了最大的成功。血液系統惡性腫瘤也呈現類似的成長勢頭，這得益於其創新的作用機制。連接子技術對於提高 ADC 的穩定性和療效至關重要。可裂解連接子能夠實現藥物在腫瘤部位的精準釋放，並展現出性能優勢。不可裂解連接子也因其更高的治療指數而備受關注。含有細胞毒性藥物（例如奧瑞他汀類和美登素類）的有效載荷因其強大的抗腫瘤活性而具有巨大的成長潛力。拓樸異構酶抑制劑等新興有效載荷因其提供新的治療方法而備受關注。策略合作和研發投入正在推動市場成長，促進創新，並拓展 ADC 產品線。

市場區隔
類型 單株抗體、連接子和細胞毒性藥物
產品 Adcetris、卡西拉、恩赫茲、特羅德爾維、波利維
服務 契約製造、合約研究和臨床試驗服務
科技 可切割連接子、不可切割連接子、位點特異性連接
適應症 乳癌、淋巴瘤、白血病、肺癌、攝護腺癌、卵巢癌
最終用戶 醫院、專科診所、研究機構、製藥公司
過程 研發、製造、品管
步 藥物發現、臨床前研究、臨床研究、商業化
解決方案 客製化抗體開發、抗體工程、連接子開發
給藥途徑 靜脈注射和皮下注射

市場概況：

抗體藥物複合體(ADC) 市場正經歷著市場佔有率和定價策略的動態變化。各公司正利用創新的定價模式來提高藥物的可及性並促進其廣泛應用。新產品的推出至關重要，領先的製藥公司正不斷推出尖端 ADC 以滿足尚未滿足的醫療需求。這種競爭格局的特點是策略聯盟和夥伴關係關係，旨在拓展治療產品組合併鞏固市場影響。對個人化醫療和標靶治療的關注正在推動市場成長，北美憑藉其先進的醫療基礎設施和強大的研發實力保持著主導地位。 ADC 市場的競爭日益激烈，主要企業正大力投資研發以維持其競爭優勢。對行業領先企業的比較分析表明，它們都注重創新和療效。監管至關重要，ADC 的核准和商業化受到嚴格的指導方針約束。歐洲藥品管理局 (EMA) 和美國食品藥物管理局(FDA) 在塑造市場動態發揮關鍵作用。遵守這些法規是進入和拓展市場的必要條件。隨著技術的進步和對精準腫瘤學的日益重視，該市場的未來前景光明。

主要趨勢和促進因素：

抗體藥物複合體(ADC) 市場正經歷強勁成長，這主要得益於標靶癌症治療和個人化醫療的進步。關鍵趨勢包括新型連接子和有效載荷的整合，從而提高治療的療效和安全性。製藥公司正加大研發投入，以創新和拓展其 ADC 產品組合。此外，全球癌症發生率的上升也推動了對更有效治療方法的需求。監管部門的核准和有利的報銷政策進一步促進了市場擴張。全球人口老化也是導致癌症發生率上升的原因之一，進一步推動了市場成長。生技公司與學術機構之間的合作正在加速創新步伐。此外，在非腫瘤領域開發 ADC 的趨勢日益明顯，拓寬了治療應用範圍。新興市場醫療基礎設施的改善和對先進療法認知度的提高，為市場帶來了許多機會。預計該市場將持續成長。

限制與挑戰：

抗體藥物複合體（ADC）市場面臨許多重大限制與挑戰。其中一個關鍵限制因素是ADC的高昂研發和生產成本，這可能阻礙中小企業進入市場。複雜的生產流程和嚴格的監管要求加重了企業的財務負擔，限制了市場擴張。另一個挑戰是缺乏熟悉ADC技術的專業人才。人才短缺會減緩創新和研發，並可能影響市場成長。此外，ADC的複雜性可能引發穩定性和安全性方面的擔憂，需要進行廣泛的研究和測試以確保療效和患者安全。同時，競爭格局日益激烈，眾多公司爭奪市場佔有率，可能導致價格壓力。最後，對個人化醫療解決方案和客製化ADC療法的需求使大規模生產變得更加複雜，帶來了物流和擴充性的挑戰。所有這些因素共同限制了ADC市場的成長潛力。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 單株抗體
    • 連接器
    • 細胞毒性物質
  • 市場規模及預測：依產品分類
    • ADCETRIS
    • 門頭
    • 恩赫茲
    • 托羅德爾比
    • 聚維
  • 市場規模及預測：依服務分類
    • 契約製造
    • 委託研究
    • 臨床試驗服務
  • 市場規模及預測：依技術分類
    • 可裂解連接子
    • 不可切割的連接子
    • 位點特異性結合
  • 市場規模及預測：依應用領域分類
    • 乳癌
    • 淋巴瘤
    • 白血病
    • 肺癌
    • 攝護腺癌
    • 卵巢癌
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 專科診所
    • 研究所
    • 製藥公司
  • 市場規模及預測：依製程分類
    • 研究與開發
    • 製造業
    • 品管
  • 市場規模及預測：依發展階段分類
    • 藥物發現
    • 臨床前階段
    • 臨床
    • 商業化
  • 市場規模及預測：按解決方案分類
    • 客製化抗體開發
    • 抗體工程
    • 連接子開發
  • 市場規模及預測：依管理途徑
    • 靜脈注射
    • 皮下注射

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Seattle Genetics
  • ImmunoGen
  • Mersana Therapeutics
  • ADC Therapeutics
  • Sutro Biopharma
  • Heidelberg Pharma
  • MabPlex International
  • Concortis Biotherapeutics
  • Abzena
  • NBE-Therapeutics
  • Synthon Biopharmaceuticals
  • Alligator Bioscience
  • Zymeworks
  • AstraZeneca Biologics
  • Avid Bioservices

第9章：關於我們

簡介目錄
Product Code: GIS33629

Antibody Drug Conjugate Market is anticipated to expand from $21 billion in 2024 to $43.9 billion by 2034, growing at a CAGR of approximately 7.7%. The Antibody Drug Conjugate Market encompasses therapeutics that combine monoclonal antibodies with cytotoxic agents, targeting specific cancer cells while minimizing damage to healthy tissues. This market is driven by advancements in targeted cancer therapies, increasing cancer prevalence, and technological innovations in drug delivery systems. The market's growth is further propelled by ongoing clinical trials, regulatory approvals, and strategic collaborations among key industry players.

The Antibody Drug Conjugate (ADC) Market is experiencing robust expansion, driven by advancements in targeted cancer therapies and personalized medicine. The oncology segment is at the forefront, with breast cancer and hematologic malignancies being primary areas of focus due to high unmet needs. Within this segment, breast cancer ADCs are the top performers, offering promising clinical outcomes. Hematologic ADCs follow closely, capitalizing on innovative mechanisms of action. The linker technology segment is pivotal, enhancing ADC stability and efficacy. Cleavable linkers lead in performance, facilitating precise drug release at tumor sites. Non-cleavable linkers also gain traction, offering improved therapeutic indices. The payload segment, featuring cytotoxic agents like auristatins and maytansinoids, shows significant growth potential, driven by their potent anti-tumor activity. Emerging payloads, such as topoisomerase inhibitors, are gaining attention as they offer novel therapeutic avenues. Strategic collaborations and investments in research and development are propelling market growth, fostering innovation and expanding the ADC pipeline.

Market Segmentation
TypeMonoclonal Antibodies, Linkers, Cytotoxins
ProductAdcetris, Kadcyla, Enhertu, Trodelvy, Polivy
ServicesContract Manufacturing, Contract Research, Clinical Trial Services
TechnologyCleavable Linker, Non-cleavable Linker, Site-specific Conjugation
ApplicationBreast Cancer, Lymphoma, Leukemia, Lung Cancer, Prostate Cancer, Ovarian Cancer
End UserHospitals, Specialty Clinics, Research Institutes, Pharmaceutical Companies
ProcessResearch and Development, Manufacturing, Quality Control
StageDiscovery, Preclinical, Clinical, Commercialization
SolutionsCustom Antibody Development, Antibody Engineering, Linker Development
ModeIntravenous, Subcutaneous

Market Snapshot:

The Antibody Drug Conjugate (ADC) market is experiencing dynamic shifts in market share and pricing strategies. Companies are leveraging innovative pricing models to enhance accessibility and drive adoption. New product launches are pivotal, with pharmaceutical giants introducing cutting-edge ADCs to address unmet medical needs. This competitive landscape is characterized by strategic collaborations and partnerships, aiming to expand therapeutic portfolios and enhance market presence. The focus on personalized medicine and targeted therapies is propelling market growth, with North America maintaining a leadership position due to advanced healthcare infrastructure and robust R&D activities. Competition in the ADC market is intensifying, with key players investing heavily in research and development to maintain a competitive edge. Benchmarking against industry leaders reveals a focus on innovation and efficacy. Regulatory influences are significant, as stringent guidelines govern the approval and commercialization of ADCs. The European Medicines Agency and the U.S. FDA play crucial roles in shaping market dynamics. Compliance with these regulations is essential for market entry and expansion. The market's trajectory is promising, driven by technological advancements and an increasing focus on precision oncology.

Geographical Overview:

The Antibody Drug Conjugate (ADC) market is witnessing robust growth across various regions, each with unique dynamics. North America remains dominant, propelled by advanced healthcare infrastructure and substantial investment in biotechnology research. The region's strong pharmaceutical presence and focus on innovation further bolster its market leadership. Europe follows, with significant investments in healthcare research and a supportive regulatory environment fostering a thriving ADC market. The Asia Pacific region is experiencing rapid expansion, driven by increasing healthcare needs and rising investments in biotechnology. Countries like China and India are emerging as key players, with growing pharmaceutical industries and supportive government policies. Latin America and the Middle East & Africa are promising new growth pockets. In Latin America, the market benefits from rising healthcare expenditure and improved access to advanced therapies, while the Middle East & Africa are recognizing the potential of ADCs in addressing unmet medical needs and enhancing treatment outcomes.

Key Trends and Drivers:

The Antibody Drug Conjugate Market is experiencing robust growth, propelled by advances in targeted cancer therapies and personalized medicine. A key trend is the integration of novel linkers and payloads, enhancing the efficacy and safety of these therapies. Pharmaceutical companies are increasingly investing in research and development to innovate and expand their ADC portfolios. Moreover, the growing prevalence of cancer globally is driving demand for more effective treatment options. Regulatory approvals and favorable reimbursement policies are further facilitating market expansion. The aging global population also contributes to the increasing incidence of cancer, thereby boosting market growth. Collaborations between biotech firms and academic institutions are accelerating the pace of innovation. Additionally, there is a rising trend towards the development of ADCs for non-oncological indications, broadening the scope of therapeutic applications. Opportunities abound in emerging markets where healthcare infrastructure is improving, and awareness of advanced therapies is on the rise. This market is poised for sustained expansion.

Restraints and Challenges:

The Antibody Drug Conjugate (ADC) market is confronted with several significant restraints and challenges. A primary restraint is the high cost of ADC development and production, which can deter smaller companies from entering the market. The complex manufacturing processes and stringent regulatory requirements add to the financial burden, limiting market expansion. Another challenge is the limited availability of skilled professionals with expertise in ADC technology. This scarcity can slow innovation and development, impacting market growth. Additionally, the intricate nature of ADCs can lead to stability and safety concerns, requiring extensive research and testing to ensure efficacy and patient safety. Furthermore, the competitive landscape is intensifying, with numerous players vying for market share, which can lead to pricing pressures. Lastly, the need for personalized medicine solutions and tailored ADC therapies complicates mass production efforts, posing logistical and scalability challenges. These factors collectively restrain the ADC market's growth potential.

Key Players:

Seattle Genetics, ImmunoGen, Mersana Therapeutics, ADC Therapeutics, Sutro Biopharma, Heidelberg Pharma, MabPlex International, Concortis Biotherapeutics, Abzena, NBE-Therapeutics, Synthon Biopharmaceuticals, Alligator Bioscience, Zymeworks, AstraZeneca Biologics, Avid Bioservices

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Solutions
  • 2.10 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Linkers
    • 4.1.3 Cytotoxins
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Adcetris
    • 4.2.2 Kadcyla
    • 4.2.3 Enhertu
    • 4.2.4 Trodelvy
    • 4.2.5 Polivy
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Contract Manufacturing
    • 4.3.2 Contract Research
    • 4.3.3 Clinical Trial Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cleavable Linker
    • 4.4.2 Non-cleavable Linker
    • 4.4.3 Site-specific Conjugation
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Breast Cancer
    • 4.5.2 Lymphoma
    • 4.5.3 Leukemia
    • 4.5.4 Lung Cancer
    • 4.5.5 Prostate Cancer
    • 4.5.6 Ovarian Cancer
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Specialty Clinics
    • 4.6.3 Research Institutes
    • 4.6.4 Pharmaceutical Companies
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Research and Development
    • 4.7.2 Manufacturing
    • 4.7.3 Quality Control
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Discovery
    • 4.8.2 Preclinical
    • 4.8.3 Clinical
    • 4.8.4 Commercialization
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Custom Antibody Development
    • 4.9.2 Antibody Engineering
    • 4.9.3 Linker Development
  • 4.10 Market Size & Forecast by Mode (2020-2035)
    • 4.10.1 Intravenous
    • 4.10.2 Subcutaneous

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Stage
      • 5.2.1.9 Solutions
      • 5.2.1.10 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Stage
      • 5.2.2.9 Solutions
      • 5.2.2.10 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Stage
      • 5.2.3.9 Solutions
      • 5.2.3.10 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Stage
      • 5.3.1.9 Solutions
      • 5.3.1.10 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Stage
      • 5.3.2.9 Solutions
      • 5.3.2.10 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Stage
      • 5.3.3.9 Solutions
      • 5.3.3.10 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Stage
      • 5.4.1.9 Solutions
      • 5.4.1.10 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Stage
      • 5.4.2.9 Solutions
      • 5.4.2.10 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Stage
      • 5.4.3.9 Solutions
      • 5.4.3.10 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Stage
      • 5.4.4.9 Solutions
      • 5.4.4.10 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Stage
      • 5.4.5.9 Solutions
      • 5.4.5.10 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Stage
      • 5.4.6.9 Solutions
      • 5.4.6.10 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Stage
      • 5.4.7.9 Solutions
      • 5.4.7.10 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Stage
      • 5.5.1.9 Solutions
      • 5.5.1.10 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Stage
      • 5.5.2.9 Solutions
      • 5.5.2.10 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Stage
      • 5.5.3.9 Solutions
      • 5.5.3.10 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Stage
      • 5.5.4.9 Solutions
      • 5.5.4.10 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Stage
      • 5.5.5.9 Solutions
      • 5.5.5.10 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Stage
      • 5.5.6.9 Solutions
      • 5.5.6.10 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Stage
      • 5.6.1.9 Solutions
      • 5.6.1.10 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Stage
      • 5.6.2.9 Solutions
      • 5.6.2.10 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Stage
      • 5.6.3.9 Solutions
      • 5.6.3.10 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Stage
      • 5.6.4.9 Solutions
      • 5.6.4.10 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Stage
      • 5.6.5.9 Solutions
      • 5.6.5.10 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Seattle Genetics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 ImmunoGen
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Mersana Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 ADC Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Sutro Biopharma
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Heidelberg Pharma
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 MabPlex International
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Concortis Biotherapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Abzena
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 NBE-Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Synthon Biopharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Alligator Bioscience
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Zymeworks
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 AstraZeneca Biologics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Avid Bioservices
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us